Lexeo Therapeutics (NASDAQ:LXEO) Given “Buy” Rating at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Tuesday,Benzinga reports. They presently have a $17.00 price objective on the stock. Chardan Capital’s price target would suggest a potential upside of 109.36% from the stock’s current price.

Several other research firms have also recently issued reports on LXEO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. HC Wainwright lowered their price objective on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Cantor Fitzgerald began coverage on Lexeo Therapeutics in a research note on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective on the stock. Finally, Leerink Partners lifted their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Lexeo Therapeutics Trading Down 23.0%

NASDAQ:LXEO opened at $8.12 on Tuesday. The stock’s 50 day simple moving average is $9.48 and its 200-day simple moving average is $7.10. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $10.99. The firm has a market cap of $592.68 million, a P/E ratio of -3.01 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.15. Research analysts forecast that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $117,409.02. Following the completion of the sale, the chief executive officer owned 242,118 shares of the company’s stock, valued at approximately $2,164,534.92. This trade represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tai Sandi See sold 3,888 shares of Lexeo Therapeutics stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the sale, the insider owned 65,862 shares of the company’s stock, valued at approximately $588,806.28. This represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 24,646 shares of company stock worth $221,037. 5.30% of the stock is owned by corporate insiders.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC boosted its holdings in Lexeo Therapeutics by 10.6% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock valued at $110,000 after acquiring an additional 1,595 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Lexeo Therapeutics by 6.1% in the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after purchasing an additional 1,626 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after buying an additional 2,342 shares during the period. AXQ Capital LP raised its stake in shares of Lexeo Therapeutics by 19.6% during the third quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock worth $99,000 after buying an additional 2,446 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Lexeo Therapeutics by 42.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock valued at $63,000 after buying an additional 2,799 shares during the period. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.